Non-alcoholic fatty liver disease (NAFLD): assessment and management
National Institute for Health and Care Excellence 2016
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.
Keywords: platelet ratio index; acoustic radiation force impulse; alanine transaminase; aspartate aminotransferase; body mass index; controlled attenuation parameter; coronary heart disease; plasma cytokeratin 18; chronic kidney disease; cardiovascular disease; docosahexaenoic acid; diabetes mellitus; liver fibrosis; eicosapentaenoic acid; fibrosis diagnostic test; fatty liver index; gamma-glutamyl-transferase; glycated haemoglobin; hepatitis B surface antigen; hepatitis B virus; hepatitis C virus; high-density lipoprotein; homeostatic model; low-density lipoprotein; myocardial infarction; magnetic resonance elastography; magnetic resonance imaging; MRI proton density fat fraction; MRI relative signal intensity decrease; magnetic resonance spectroscopy; metabolic syndrome; non-alcoholic fatty liver disease; NAFLD activity score; non-alcoholic steatohepatitis; NASH clinical research; network; peripheral artery disease; polycystic ovarian syndrome; polyunsaturated fatty acid; quantitative insulin sensitivity check index; transient elastography; type 2 diabetes; transient ischaemic attack; very low calorie diet; confidence interval
National Institute for Health and Care Excellence (NICE)